


We claim:

1. A compound of formula (I)



p is 0, 1, or 2;

y is 0, 1, or 2; and z is 0, 1, or 2;

X<sub>1</sub> is CH<sub>2</sub>, CH, or N; to form a indolinyl, indolyl, or benzimidazole ring respectively and including applicable double bonds and/or hydrogen atoms;


X<sub>2</sub> is CH or N;

R<sup>1</sup> and R<sup>2</sup> are independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, phenyl, C<sub>1</sub>-C<sub>10</sub> alkylaryl, SO<sub>2</sub>R<sup>8</sup>, (CH<sub>2</sub>)<sub>n</sub>C(O)NR<sup>8</sup>R<sup>8</sup>, SO<sub>2</sub>C<sub>1</sub>-C<sub>10</sub> alkylaryl, SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylheterocyclic, C<sub>4</sub>-C<sub>10</sub> alkylcycloalkyl, (CH<sub>2</sub>)<sub>n</sub>C(O)OR<sup>8</sup>, and (CH<sub>2</sub>)<sub>n</sub>C(O)R<sup>8</sup>; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to two groups independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, phenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>1</sub>-C<sub>8</sub> alkylaryl, and C(O)C<sub>1</sub>-C<sub>8</sub> alkyl; and wherein R<sup>1</sup> and R<sup>2</sup> may optionally combine with each other to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen-containing heterocycle may further have substituents selected from the group consisting of oxo, amino, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, phenyl, C<sub>1</sub>-C<sub>3</sub> alkylaryl, C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, halo, C<sub>1</sub>-C<sub>3</sub> haloalkyl; R<sup>3</sup> and R<sup>3'</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, phenyl, aryl, C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, and C<sub>1</sub>-C<sub>8</sub> alkylaryl; R<sup>4</sup> and R<sup>5</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, C<sub>1</sub>-C<sub>8</sub> haloalkyl, phenyl, aryl, C<sub>1</sub>-C<sub>8</sub> alkylaryl, (CH<sub>2</sub>)<sub>m</sub>NSO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkyl, (CH<sub>2</sub>)<sub>m</sub>NSO<sub>2</sub>phenyl, (CH<sub>2</sub>)<sub>m</sub>NSO<sub>2</sub>aryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, and -C(O)OC<sub>1</sub>-C<sub>8</sub> alkyl; wherein each R<sup>4</sup> and R<sup>5</sup> is attached to its respective ring only at carbon atoms; wherein m is 1 or 2;

$R^6$  and  $R^7$  are each independently selected from hydrogen,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl,  $C(O)C_1$ - $C_8$  alkyl,  $SO_2C_1$ - $C_8$  alkyl,  $SO_2C_1$ - $C_8$  alkylaryl,  $SO_2C_1$ - $C_8$  alkylheterocyclic, aryl,  $C_1$ - $C_8$  alkylaryl,  $C_3$ - $C_7$  cycloalkyl,  $C_1$ - $C_6$  alkylcycloalkyl,  $(CH_2)_mC(O)OR^8$ ,  $(CH_2)_mC(O)R^8$ ,  $(CH_2)_mC(O)NR^8R^8$ , and  $(CH_2)_mNSO_2R^8$ ; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to two groups independently selected from  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl, phenyl, and  $C_1$ - $C_8$  alkylaryl; and wherein  $R^6$  and  $R^7$  may independently combine with each other, and with the nitrogen atom to which they are attached to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen containing heterocycle may optionally have substituents selected from the group consisting of oxo, amino,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, phenyl, and  $C_1$ - $C_8$  alkylaryl;

$R^8$  is independently selected from hydrogen,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl, phenyl, benzyl, and  $C_5$ - $C_8$  alkylaryl; or a pharmaceutically acceptable salt, solvate, prodrug, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof.

2. A compound of formula II



wherein  $p$  is 0, 1, or 2;

$y$  is 0, 1, or 2; and  $z$  is 0, 1, or 2;

$X_1$  is  $CH_2$ ,  $CH$ , or  $N$ ; to form a indolyl, indolyl, or benzimidazole ring respectively and including applicable double bonds and/or hydrogen atoms;

$X_2$  is  $CH$  or  $N$ ;


$R^1$  and  $R^2$  are independently selected from hydrogen,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, phenyl,  $C_1$ - $C_{10}$  alkylaryl,  $SO_2R^8$ ,  $(CH_2)_nC(O)NR^8R^8$ ,  $SO_2C_1$ - $C_{10}$  alkylaryl,

$\text{SO}_2\text{C}_1\text{-C}_8$  alkylheterocyclic,  $\text{C}_4\text{-C}_{10}$  alkylcycloalkyl,  $(\text{CH}_2)_n\text{C(O)OR}^8$ , and  $(\text{CH}_2)_n\text{C(O)R}^8$ ; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to two groups independently selected from  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_2\text{-C}_8$  alkenyl, phenyl,  $\text{C}_3\text{-C}_8$  cycloalkyl,  $\text{C}_1\text{-C}_8$  alkylaryl, and  $\text{C(O)C}_1\text{-C}_8$  alkyl; and wherein  $\text{R}^1$  and  $\text{R}^2$  may optionally combine with each other to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen-containing heterocycle may further have substituents selected from the group consisting of oxo, amino,  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_2\text{-C}_8$  alkenyl,  $\text{C}_2\text{-C}_8$  alkynyl, phenyl,  $\text{C}_1\text{-C}_3$  alkylaryl,  $\text{C(O)C}_1\text{-C}_8$  alkyl,  $\text{CO(O)C}_1\text{-C}_8$  alkyl, halo,  $\text{C}_1\text{-C}_3$  haloalkyl;  $\text{R}^3$  and  $\text{R}^3'$  are each independently selected from hydrogen,  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_2\text{-C}_8$  alkenyl,  $\text{C}_2\text{-C}_8$  alkynyl, phenyl, aryl,  $\text{C}_1\text{-C}_8$  alkylcycloalkyl, and  $\text{C}_1\text{-C}_8$  alkylaryl;  $\text{R}^4$  and  $\text{R}^5$  are each independently selected from hydrogen,  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_2\text{-C}_8$  alkenyl,  $\text{C}_2\text{-C}_8$  alkynyl,  $\text{C}_1\text{-C}_8$  alkoxy, halo,  $\text{C}_1\text{-C}_8$  haloalkyl, phenyl, aryl,  $\text{C}_1\text{-C}_8$  alkylaryl,  $(\text{CH}_2)_m\text{NSO}_2\text{C}_1\text{-C}_8$  alkyl,  $(\text{CH}_2)_m\text{NSO}_2$  phenyl,  $(\text{CH}_2)_m\text{NSO}_2$  aryl,  $-\text{C(O)C}_1\text{-C}_8$  alkyl, and  $-\text{C(O)OC}_1\text{-C}_8$  alkyl; wherein each  $\text{R}^4$  and  $\text{R}^5$  is attached to its respective ring only at carbon atoms; wherein  $m$  is 1 or 2; and  $n$  is 1, 2, or 3;  $\text{R}^6$  and  $\text{R}^7$  are each independently selected from hydrogen,  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_2\text{-C}_8$  alkenyl,  $\text{C}_2\text{-C}_8$  alkynyl,  $\text{C(O)C}_1\text{-C}_8$  alkyl,  $\text{SO}_2\text{C}_1\text{-C}_8$  alkyl,  $\text{SO}_2\text{C}_1\text{-C}_8$  alkylaryl,  $\text{SO}_2\text{C}_1\text{-C}_8$  alkylheterocyclic,  $\text{C}_1\text{-C}_8$  alkylaryl,  $\text{C}_3\text{-C}_7$  cycloalkyl,  $\text{C}_1\text{-C}_6$  alkylcycloalkyl, aryl,  $(\text{CH}_2)_m\text{C(O)OR}^8$ ,  $(\text{CH}_2)_m\text{C(O)R}^8$ ,  $(\text{CH}_2)_m\text{C(O)NR}^8\text{R}^8$ , and  $(\text{CH}_2)_m\text{NSO}_2\text{R}^8$ ; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to two groups independently selected from  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_2\text{-C}_8$  alkenyl, phenyl, and  $\text{C}_1\text{-C}_8$  alkylaryl; and wherein  $\text{R}^6$  and  $\text{R}^7$  may independently combine with each other, and with the nitrogen atom to which they are attached to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen containing heterocycle may optionally have substituents selected from the group consisting of oxo, amino,  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_2\text{-C}_8$  alkenyl,  $\text{C}_2\text{-C}_8$  alkynyl, phenyl, and  $\text{C}_1\text{-C}_8$  alkylaryl;  $\text{R}^8$  is independently selected from hydrogen,  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_2\text{-C}_8$  alkenyl, phenyl, benzyl, and  $\text{C}_5\text{-C}_8$  alkylaryl; or a pharmaceutically acceptable salt, solvate, prodrug, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof.

3. A compound according to Claim 1 wherein  $\text{X}_1$  is  $\text{CH}$  and  $\text{X}_2$  is selected  $\text{CH}$ .

4. A compound according to Claim 1 wherein  $X_1$  is CH and  $X_2$  is selected N.
5. A compound according to Claim 1 wherein  $X_1$  is N, and  $X_2$  is CH.
6. A compound according to Claim 1 wherein  $X_1$  is N, and  $X_2$  is N.
7. A compound according to Claim 1 wherein y is 0 or 1, and  $R^4$  is independently selected from the group consisting of fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl, benzyl and ethoxy.
8. A compound according to Claim 1 wherein z is 0 or 1, and  $R^5$  is independently selected from the group consisting of fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl, and benzyl.
9. A compound according to Claim 2 wherein  $X_1$  is CH and  $X_2$  is selected CH.
10. A compound according to Claim 2 wherein  $X_1$  is CH and  $X_2$  is selected N.
11. A compound according to Claim 2 wherein  $X_1$  is N, and  $X_2$  is CH.
12. A compound according to Claim 2 wherein  $X_1$  is N, and  $X_2$  is N.
13. A compound according to Claim 2 wherein y is 0 or 1, and  $R^4$  is independently selected from the group consisting of fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl, benzyl and ethoxy.
14. A compound according to Claim 2 wherein z is 0 or 1, and  $R^5$  is independently selected from the group consisting of fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl, and benzyl.

15. A compound according to Claim 1 or 2 wherein R<sup>1</sup> and R<sup>2</sup> are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, 2-methylpentyl, t-butyl, cyclopropyl, phenyl,



16. The compound according to Claim 1 or 2 wherein  $R^6$  and  $R^7$  are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, and phenyl.

17. A compound selected from the group consisting of:

#### 4-{5-[(3-Methyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,

## 4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-{5-[(3,3-Dimethyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,

## 4-{5-[(3-Methyl-butylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,

## 4-{5-[(3,3-Dimethyl-butylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide, (E)-

#### 4-(5-Hexylaminomethyl-indol-1-ylmethyl)-benzamide,

### 4-{5-[(3-Phenyl-propylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-(5-{{[2-(2-Fluoro-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,

### 4-{5-[(2-Hydroxy-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-(5-{{2-(4-Methoxy-phenyl)-ethylamino}-methyl}-indol-1-ylmethyl)-benzamide,

## 4-{5-[{(2-Chloro-6-fluoro-benzylamino)-methyl]-indol-1-ylmethyl}-benzamide,

4-{5-[(2-Pyridin-3-yl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,  
4-(5-[[2-(2-Ethoxy-phenyl)-ethylamino]-methyl]-indol-1-ylmethyl)-benzamide,  
4-(5-[[2-(Tetrahydro-pyran-4-yl)-ethylamino]-methyl]-indol-1-ylmethyl)-benzamide,  
4-{5-[(2-Cyclohex-1-enyl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,  
4-(5-[[2-(3-Fluoro-phenyl)-ethylamino]-methyl]-indol-1-ylmethyl)-benzamide,  
4-{5-[(2-Ethyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,  
1-{4-[(3-Methyl-butylamino)-methyl]-benzyl}-2,3-dihydro-1H-indole-5-carboxylic acid  
amide or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer and  
diastereomeric mixture thereof.

18. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I or II or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer or diastereomeric mixture thereof in association with a carrier, diluent and/or excipient.

18. A method for blocking a mu, kappa, delta or receptor combination (heterodimer) thereof in mammals comprising administering to a mammal requiring blocking of a mu, kappa, delta or receptor combination (heterodimer) thereof, a receptor blocking dose of a compound of formula I or II or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer or diastereomeric mixture thereof.

19. A method of treating or preventing obesity and Related Diseases comprising administering a therapeutically effective amount of a compound of formula I or II.

20. A method according to Claim 19 wherein the Related Diseases is selected from the group consisting of diabetes, diabetic complications, diabetic retinopathy, atherosclerosis, hyperlipidemia, hypertriglyceremia, hyperglycemia, and hyperlipoproteinemia.

21. A method of treating and/or preventing diseases related to obesity including irritable bowel syndrome, nausea, vomiting, depression, smoking and alcohol

addiction, sexual dysfunction, substance abuse, drug overdose, addictive behavior disorders, compulsive behaviors, and stroke comprising administering a therapeutically effective amount of a compound of formula I or II.

22. A method of suppressing appetite in a patient in need thereof, comprising administering a therapeutically effective amount of a compound of formula I or II.

23. Use of a compound of formula I or II in the manufacture of a medicament for the treatment and/or amelioration of the symptoms associated with obesity and Related Diseases comprising administering a therapeutically effective amount of a compound of formula I or II to a patient in need thereof.